AK104(SC) + AK104(IV) + Capecitabine + Oxaliplatin injection
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric / Gastroesophageal Junction Adenocarcinoma
Conditions
Gastric / Gastroesophageal Junction Adenocarcinoma
Trial Timeline
Mar 31, 2026 → Feb 15, 2028
NCT ID
NCT07449780About AK104(SC) + AK104(IV) + Capecitabine + Oxaliplatin injection
AK104(SC) + AK104(IV) + Capecitabine + Oxaliplatin injection is a phase 3 stage product being developed by Akeso for Gastric / Gastroesophageal Junction Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07449780. Target conditions include Gastric / Gastroesophageal Junction Adenocarcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07449780 | Phase 3 | Recruiting |
Competing Products
20 competing products in Gastric / Gastroesophageal Junction Adenocarcinoma